News Releases

Universal H7N9 vaccine generates protective HAI antibodies against unmatched influenza strain in 100% of tested animals; also shows how quickly Inovio can respond to a pandemic threat

Polyvalent Vaccine Design Stimulates Significant Antibody and T-Cell Responses with 100% Survival Against Multiple Families of Most Lethal Virus Known to Man

Broadly targeted SynCon® H1N1 vaccine induces protective antibodies comparable to current seasonal vaccine against currently circulating influenza strain

Biotech recognized for VGX-3100, an innovative therapy for pre-cancers and cancers caused by HPV, now in phase II for cervical dysplasia

Inovio to Advance Painless Device to Simultaneously Deliver Multiple Vaccines Using Electroporation Technology

Inovio Plans to Initiate Phase I/IIa Study of its Proprietary, Next Generation HCV Therapeutic Vaccine in 2013

Company invites individual and institutional investors to log-on to view presentation

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference

Phase I/IIa Trial Follows Preclinical Study Demonstrating for First Time that a Multi-Antigen HCV Vaccine Can Generate Potent T-Cell Response in Liver

Follow-on Agreement Will Lead to Clinical Trials

Clinical Trial with Universal Vaccine Increases Response Rate of Subjects Generating Infection-Preventing Antibodies by 100% in Population Most at Risk for Flu Deaths

No Vaccine or Cure Exists For Virus That Can Be Life Threatening to Infants, Immune Compromised, and Transplant Patients; Highly Pervasive Virus Also Implicated in Cancers, Inflammatory Diseases, and Cardiovascular Diseases

Biotech Broadens IP Encompassing Synthetic Vaccines Against Cancer, Infectious Disease and Biodefense Pathogens

Inovio Advances New Disease Therapy, Where 400 Million Patients Lack Effective Treatment

Plasmid Therapy Increases Live Births in Pigs; Previously Approved in Australia